Despite the combination of anti-PD-1 and anti-CTLA4 inhibitors being more effective than either agent alone, dual immune checkpoint blockade therapy induces a higher prevalence of ICI-DM. This evidence concerns the gene CTLA4 and diabetes mellitus.